Table 1 Examples of drugs approved for sale subsequently withdrawn from the market due to liver and cardiac toxicity
Drug | Year | Reason for withdrawal |
|---|---|---|
Terfenadine (Seldane) | 1998 | Risk of cardiac arrhythmias |
Alpidem (Ananxyl) | 1999 | Rare serious hepatotoxicity |
Grepafloxacin (Raxar) | 1999 | Prolonged QT interval |
Troglitazone (Rezulin) | 2000 | Risk of hepatotoxicity |
Trovafloxacin (Trovan) | 2001 | Risk of liver failure |
Rofecoxib (Vioxx) | 2004 | Risk of myocardial infarction |
Rosiglitazone (Avandia) | 2010 | Withdrawn in Europe because of increased risk of myocardial infarction and death. This drug continues to be available in the USA |